OptiNose (OPTN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
November 10, 2022 7:00 AM ESTCompany plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023
Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCEs Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients
Company reports third quarter 2022 XHANCE net revenue of $20.1 million
Company expects full year 2022 XHANCE net revenue to be between $74 to $78 million
Company expects full year 2022 operating expenses to be between $127 to $131 million; full year 2023 operating expenses... More
